CTOs on the Move

Windtree Therapeutics

www.windtreetx.com

 
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.windtreetx.com
  • 2600 Kelly Road Suite 100
    Warrington, PA USA 18976
  • Phone: 215.488.9300

Executives

Name Title Contact Details

Funding

Windtree Therapeutics raised $26.4M on 12/09/2019
Windtree Therapeutics raised $23M on 05/20/2020

Similar Companies

Xpress Wellness Urgent Care

Xpress Wellness provides urgent care, primary care, and occupational medicine. Walk in, check in online, or schedule a virtual visit today.

Keysource Medical

KeySource Medical, Inc. (KMI) has been supplying the generic pharmaceutical needs of retail pharmacies across the United States since 1996. Our sales force is focused on serving the interests of our customers, emphasizing the highest level of service, integrity and value. As a trusted wholesale distributor of generic pharmaceuticals, we take our responsibility to safeguard the integrity of the pharmaceutical supply chain seriously, securing it against counterfeit or adulterated products. • KeySource purchases ALL products it sells directly from FDA approved manufacturers. • KeySource has received VAWD (Verified-Accredited Wholesale Distributor) accreditation from the National Association of Boards of Pharmacy. • KeySource is an active member of HDMA (Healthcare Distribution Management Association), a National Association comprised of America`s largest pharmaceutical distributors KMI has been recognized by “INC. Magazine” as one of America`s fastest growing, privately-held companies, placing #162 on the “INC. 500” list in 2006. In 2009, KMI was a finalist and category winner in the “Fast 55” competition sponsored by the Cincinnati Business Courier. KeySource Medical is committed to serving the community through the Dennis J. Engel Giving Program. We help make it possible to serve the uninsured and those in need with prescriptions at no cost through The St. Vincent de Paul Charitable Pharmacy.

Hoodia Products

Hoodia Products is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mustang Bio

Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.

Precision for Medicine

At Precision for Medicine, we help our pharmaceutical and life sciences clients innovate, develop, and commercialize next generation medical products. Backed by a diverse team of experts across the spectrum of the healthcare marketplace, we provide a comprehensive and integrated set of services that help accelerate research, enable market adoption, enhance patient outcomes, and realize the full commercial potential of new therapies and products.